Microfluidic mixing for the controlled, tuned and fully scalable manufacture of nanomedicines
Precision NanoSystems’ proprietary NanoAssemblr™ Platform enables the rapid and controlled manufacture of nanomedicines (liposomes, lipid nanoparticles, polymeric nanoparticles). It enables controlled, bottom-up, molecular self-assembly of nanoparticles via custom-engineered microfluidic mixing cartridges that allow millisecond mixing of nanoparticle components at the nanolitre scale. Rapid mixing on a small scale allows reproducible control over particle synthesis. The NanoAssemblr Platform solves significant issues associated with incumbent nanoparticle manufacturing such as tuning for size. The platform is ideally suited for nanoparticle research and nucleic acid delivery to primary cells.
APPLICATION NOTE
The microfluidic approach to nanoparticle research and synthesis is at the heart of the NanoAssemblr Platform. Users can control size by process and composition, and adjust parameters such as mixing ratio, flow rate and lipid composition in order to fine-tune nanoparticle size, encapsulation efficiency and much more. The system’s technology enables nanoparticle manufacturing scale-up through microfluidic reactor parallelization similar to the arraying of transistors on an integrated chip. Superior design ensures that the platform is fast and easy to use with a software controlled manufacturing process. This usability allows for the simplified transfer of manufacturing protocols between sites, which accelerates clinical development, reduces waste and ultimately saves money.
| PUBLICATIONS |
The NanoAssemblr Spark has an operating nanoparticle formulation volume of 25 – 250 μL. By ensuring yields nearing 100%, the Spark is ideal for target validation screening and nanoparticle formulation development that involves scarce or expensive nucleic acid constructs and nanoparticle excipients.
REQUEST QUOTE
The NanoAssemblr Benchtop system is designed for rapid prototyping of novel nanoparticle formulations of 1 to 15mL, that would be difficult to make with alternative manufacturing methods. Software enables the control of input mixing parameters for optimizing particle characteristics such as size and encapsulation efficiency.
REQUEST QUOTE
The NanoAssemblr Blaze bridges the gap between nanoparticle discovery and clinical development. The system can manufacture between 10 mL and 1 L which allows researchers to use the Blaze for nanoparticle discovery, for preclinical toxicology testing, and for early Chemistry, Manufacturing and Controls (CMC) studies.
REQUEST QUOTE
